Effect of Diabetes Treatment-Related Attributes on Costs to Type 2 Diabetes Patients in a Real-World Population

Abstract

Funding from Sanofi supported this study. Tong was an employee of ProUnlimited, under contract with Sanofi during the time of the study. Kitio-Dschassi was a Sanofi employee at time of the analysis. Meng, Casciano, Stern, and Gultyaev are employees of LASER Analytica, which received research funds from Sanofi to conduct this database analysis. Lee was an employee at LASER Analytica at the time of the analysis and has received grants from Sanofi. This manuscript was presented as a poster at the American Diabetes Association, 76th Scientific Sessions; New Orleans, Louisiana; June 10-14, 2016. Study concept and design were contributed by Meng, Casciano, Gultyaev, and Kitio-Dschassi. Meng and Stern collected the data, and data interpretation was performed by Casciano, Lee, Tong, and Kitio-Dschassi. The manuscript was written primarily by Lee, along with Meng and Stern, and revised by Stern, Meng, Tong, Kitio-Dschassi, and Lee.

Drug treatment of type 2 diabetes: Its cost is significantly associated with HbA1c levels

“…Ourresults are supported by data from other authors . Heald et al, using available data from a large number of general practitioners (GP) in England, looked at how medication prescription and other factors influence outcomes in their T2D population .…”

“…Ourresults are supported by data from other authors. 14 control, and also found both GP delivering increased glycaemic control (≤7.5%) and those with a lower number of patients at glycaemic risk (patients with HbA1c > 10%) was spending less in their overall prescribing costs for each patient with T2D. 22 Furthermore, Oglesby et al also reported a significant increase in the annual diabetes-related costs from US$1505 in patients with…”

“…On line with this situation, data in the literature dealing with decreasing cost of T2D mainly focus on the long‐term complications of the disease that negatively impact on life quality and economical costs. However, it is likely that drug therapy for diabetes could also significantly affect the use of costly resources . In this regard, some evidence suggests that better glycaemic control of people with T2D may be associated with lower yearly health care resource use and costs .…”

The Cost-effectiveness of a Flash Glucose Monitoring System for Management of Patients with Type 2 Diabetes Receiving Intensive Insulin Treatment in Sweden

“…In this scenario, all-cause trial-based use of resources such as ambulances, emergency room visits, and hospitalisation were implemented. Among intensive insulin users it is not possible to establish whether resource use is disease-specific due to older age and increase in comorbidities and complications, 46 – 48 and thus all-cause resource use is appropriate for scenario evaluation. In the event that these differences were driven by hypoglycaemic events, the assigned hypoglycaemic event costs were removed from the model to avoid potential double-counting.…”

Hypoglycaemia Among Insulin-Treated Patients with Diabetes: Evaluation of the United Arab Emirates cohort of the International Operations-Hypoglycaemia Assessment Tool study

“…3 Hypoglycaemia also carries an economic burden, impacting patient productivity and disease management and utilising valuable healthcare resources. 4 According to a recent meta-analysis, hypoglycaemia is prevalent among patients with type 2 diabetes mellitus (T2DM), thus necessitating an individualised approach to treatment and patient education. 5 The Canadian Hypoglycaemia Assessment Tool Program revealed high rates of hypoglycaemia among insulin-treated patients; the researchers advocated for the identification of high-risk insulin-treated patients in order to reduce the incidence of hypoglycaemia in this patient group.…”